The post-transcriptional regulatory RNA-binding protein PTBP1 functions as an inhibitor in hepatic stellate cell activation and liver fibrosis Authors: Feifan Xu, Yajun Zhou Published: 2026 ABSTRACT BackgroundHepatic stellate cell (HSC) activation is the key step in liver fibrogenesis characterized by excessive extracellular matrix (ECM) accumulation, which is based on fibrogenic factors-induced changes in gene expression in HSCs. The post-transcriptional gene-expression regulation plays a crucial role in regulation of gene expression by controlling mRNA fate through RNA binding proteins (RBPs), RBPs are essentially involved in the process of HSC activation and liver fibrogenesis. Since the activated HSCs possess the characteristics of neuron and the roles of multifunctional polypyrimidine tract binding protein 1 (PTBP1), a key RBP in inhibiting neuron differentiation, in HSC activation and liver fibrosis are elusive, this research aimed to investigate the effects of PTBP1 on HSC activation and liver fibrosis.MethodsThe study employed RNA sequencing, targeted over-expression of Ptbp1, Ptbp1 gene-knockdown mice, different mouse model of liver fibrosis, and liver samples from clinical patients.ResultsPtbp1 silencing in HSCs in vitro led to an increase in the expression of many pro-fibrotic genes, including at least the most potent fibrogenic factors, fibrogenic factor receptors, signal transducer, and ECM, but caused a decrease in the expression of pro-apoptotic genes and transcriptional factor Srebp1c, a key one to inhibiting HSC activation. Ptbp1 knockdown in mouse upregulated the expression of pro-fibrotic genes and enhanced HSC activation as well as liver fibrosis. Targeted over-expression of Ptbp1 in HSCs in the model of liver fibrosis further confirmed the effects of PTBP1 on the pro- and anti-fibrotic gene expression in HSCs, HSC activation, and liver fibrosis. Ptbp1 could bind to Srebp1c mRNA, thus inhibiting its degradation. PTBP1 also blocked PI3K/Akt pathway in HSCs. Its levels were reduced in the activated HSCs in livers from mice and clinical patients.ConclusionThis research demonstrated a previously unrecognized inhibitory effect of the multifunctional PTBP1 on HSC activation and liver fibrogenesis and the underlying mechanisms were involved in PTBP1 regulation of the important pro- or anti-fibrotic genes. Given that PTBP1 targeted lots of important pro- and anti-fibrotic genes, PTBP1 may serve as a potential therapeutic strategy for treatment of liver fibrosis.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s10020-026-01541-1. Introduction Liver fibrosis is characterized by the excessive extracellular matrix (ECM) deposition and the ‌excessive ECM are largely produced by the activated hepatic stellate cells (HSCs) (Mederacke et al. 2013). HSC activation is the key step in liver fibrogenesis (Mederacke et al. 2013) and mainly caused by fibrogenic factor-induced changes of the expression of a large number of genes. The most potent fibrogenic factors include transforming growth factor-β (TGFβ) and platelet-derived growth factor (PDGF) (Kisseleva and Brenner 2021; Dewidar et al. 2019), which bind to their receptors in HSCs and induce the changes of gene expression, thus leading to HSC activation. Gene expression is regulated at multiple levels. Post-transcriptional regulation is a crucial regulation level, which controls mRNA fate (Gerstberger et al. 2014). RNA binding proteins (RBPs) play the key role in controlling mRNA fate by binding to mRNAs (Gerstberger et al. 2014; Cook et al. 2011; Garcia-Maurino et al. 2017), thereby significantly influencing gene expression. Therefore, RBPs are essentially involved in the process of HSC activation and liver fibrogenesis. It was revealed that the disorder in RBP function leads to diseases (Gebauer et al. 2021; Fang et al. 2024). Polypyrimidine tract binding protein 1 (PTBP1) is an important and multifunctional RBP. It binds to the polypyrimidine tract of mRNA (Sawicka et al. 2008; Zhang et al. 2017), controlling its target mRNA maturation, stability, location, and translation (Sawicka et al. 2008). PTBP1 is expressed in both neurogenic cells and non-neural cells and regulates many mRNAs of different function (Gama-Carvalho et al. 2006). It is involved in various human systemic diseases such as nervous system disease and liver disease through its specific targets (Yu et al. 2024; Romanelli et al. 2013). PTBP1 was shown to bind to sterol regulatory element-binding protein 1c (Srebp1c) mRNA in hepatocytes, enhancing Srebp1c mRNA stability and transcriptional activity which in turn stimulates lipogenesis and thus promotes nonalcoholic fatty liver disease progression (Liu et al. 2018). PTBP1 also elevates cholesterol synthesis in mouse liver (Ruan et al. 2021) and is correlated with liver cancer stem cell self-renewal as well as hepatocellular carcinoma progression (Shi et al. 2022). The role of PTBP1 in liver fibrogenesis is elusive. We noted that PTBP1 was shown to play a dominant role in inhibiting neuron differentiation and maintained nonneuronal patterns of mRNAs (Yeom et al. 2018; Liang et al. 2024). It is interesting that the activated HSCs possess the characteristics of nerve cells (Li et al. 2022; Cassiman et al. 2001). For example, the activated HSCs secret neural cell synaptotagmin, nestin, neural cell adhesion molecules, neurotrophic factors and the corresponding receptors (Li et al. 2022; Cassiman et al. 2001). Moreover, neurotrophic factors promote HSC activation and liver fibrogenesis (Tao et al. 2019). Based on the crucial roles of PTBP1 in inhibiting neuron differentiation (Yeom et al. 2018; Liang et al. 2024) and the neuron characteristics of the activated HSCs (Li et al. 2022; Cassiman et al. 2001), there seemed to be a possibility that PTBP1 might play an important role in suppressing HSC activation and liver fibrogenesis. Thereby, the possibility pushed us to examine the actual role of PTBP1 in HSC activation and liver fibrogensis. Elucidation of the roles of PTBP1 in HSC activation, a key step in liver fibrosis (Mederacke et al. 2013), and clarification of the underlying mechanisms might reveal at least in part the effects of RBP on liver fibrosis and were helpful in developing new treatment approaches for liver fibrogenesis based on the roles of RBPs in liver fibrosis. Materials and methods HSC isolation and culture HSCs were isolated from male C57BL/6J mice (6-week old, Animal Research Center of Nantong University, Jiangsu, Nantong, China) as we described (Zhou et al. 2010). Briefly, mouse livers were perfused in situ with collagenase solution and pronase solution and HSC purification was performed by the density centrifugation. The purity of HSCs was assessed by an ultraviolet excited fluorescence microscope and exceeded 94%. The culture-activated HSCs were used unless otherwise specified. Transient transfection For knockdown of PTBP1 expression in HSCs, the activated mouse HSCs and human HSC cell line LX-2 (CC-Y1606, Shanghai EK-Bioscience Biotechnology Co. Ltd, Shanghai, China) were transfected with 1 μg of small interferencing RNA (siRNA) targeting mouse Ptbp1(siPTBP1(m), sc-38281, Santa cruz, CA, USA) or human PTBP1 (siPTBP1(h), sc-38280, Santa Cruz, CA, USA) or the control scrambled RNA (siControl, sc-37007, Santa Cruz) by siRNA Transfection Reagent (sc-29528, Santa Cruz, CA, USA). After incubated for 48 h, HSCs were used for RNA sequencing or real-time quantitative PCR (RT-qPCR) and Western blotting analyses. For overexpression of PTBP1 in the cultured HSCs by transfection, mouse HSCs in 6-well plastic plate were transfected with 2 μg of pcDNA3.1-PTBP1(encoding mouse PTBP1, Youbio Biotechnology Co., Ltd, Changsha, China) or pcDNA3.1/per well and Lipofectamine reagent (Life Technologies, New York, USA). HSCs were harvested for Western blotting analyses 48 h after transfection. Animal experiments and clinical samples Given that knockout of Ptbp1gene results in a homozygous lethal effect, the wild type male C57BL/6J mice (Ptbp1+/+ mice, 3 mice/each group, 6-week old) and the heterozygous Ptbp1 gene-knockout mice of C57BL/6J background (Ptbp1+/− mice, 3 mice/each group, 6-week old) were received Thioacetamide (TAA) (150 μg/g body weight, three times a week) by intraperitoneal injection (i.p.) (Tian et al. 2022). After 6-week, the livers were for RNA-sequencing or RT-qPCR or liver fibrosis analyses. The mice were from GemPharmatech Co. Ltd, Jiangsu, Nanjing, China. TAA (163678, ≥ 99.0%) was from Sigma, St. Louis, MO, USA. For testing the effects of targeted Ptbp1 over-expression in HSCs in vivo on HSC activation and liver fibrosis, the first two groups of wild type C57BL/6J mice (10 mice/each group) were given TAA (150 μg/g body weight, three times a week, i.p.) for 2 weeks, followed by tail vein injection of adeno-associated virus serotype 6 (AAV6)-Flag-mPTBP1 or AAV6-Control (5 × 1011 viral genomes (VG) in 200 μl of physiological saline/mouse, only once) for another 4-week period of TAA (Tian et al. 2022). After the treatments, HSCs were isolated from livers of 5 mice of each group for RT-qPCR analysis. The livers samples from the other 5 mice of each group were for examining liver fibrosis. The second two groups of wild type C57BL/6J mice (10 mice/each group) were received AAV6-Flag-mPTBP1 or AAV6-Control (5 × 1011 VG in 200 μl of physiological saline/mouse, only once) for 2 weeks and then underwent bile duct ligation (BDL) for another 2 weeks (Barcena-Varela et al. 2021). The liver samples were used for examining liver fibrosis. AAV6 is myfibroblast tropism (Rezvani et al. 2016). AAV6-Flag-mPTBP1 (constructed by Hanbio technology Co. Ltd, Shanghai, China) encoded flag-mouse PTBP1 under the control of mouse α-smooth muscle actin (α-SMA) promoter which was activated in HSCs but not in hepatocytes, Kupffer cells, or endothelial cells (Son et al. 2009). For detecting PTBP1 level in HSCs in fibrotic livers, the first groups of wild type C57BL/6J mice (10 mice/each group) were injected with TAA (150 μg/g body weight, three times a week, i.p.) or the vehicle for 6-week. The second groups of wild type C57BL/6J mice (10 mice/each group) were received BDL or Sham operation for 2 weeks. HSCs were isolated from the livers for analyses of Ptbp1 expression. The clinical samples of fibrotic liver tissues and the adjacent normal tissues (from 5 male patients of liver fibrosis with liver cancer, aged 51 ± 12 years) were from the affiliated nantong hospital of shanghai university (Jiangsu, Nantong, China). All the mice were housed in a condition under a 12-h light–dark diurnal cycle with 22℃−24℃ and had free access to food and water. This research was conducted in accordance with the Declaration of Helsinki and was approved by the Animal Ethics Committee of Nantong University (reference number: P20230228-002) as well as the Ethics Committee of the Affiliated Nantong Hospital of Shanghai University (Approval No. NTLYLL2019053). The consent was obtained from all the patients. RNA sequencing To investigate the downstream targets of PTBP1, the cultured HSC samples (treated with siPTBP1 or siControl) and the liver samples (from Ptbp1+/+ mice or Ptbp1+/− mice received TAA) were used for RNA sequencing performed by technicians at Shenzhen BGI Genomics Technology Co. Ltd (Guangdong, Shenzhen, China). Briefly, total RNA were extracted from HSCs and livers by TRIzol Reagent (15596018CN, Invitrogen, CA, USA), followed by library preparation and sequencing by using G400/T7/T10 platform (BGI-Shenzhen, Guangdong, China). Sequencing was applied to generate paired-end reads. Raw sequencing reads were cleaned via SOAPnuke (version 2.2.1) and then aligned to the reference mouse genome (GRCm38.p6) using HISAT2 (version 2.2.1). Gene expression levels were calculated by RSEM (version 1.3.1). Differential expression analysis was performed using DESeq2 (version 1.34.0) with genes showing Q value ≤ 0.05 considered significant. The mRNA sequencing data were deposited in NCBI Gene Expression Omnibus database with accession number GSE226992 and GSE226799. Gene Ontology (GO) (http://www.geneontology.org/) and Kyoto encyclopedia of genes and genomes (KEGG) (https://www.kegg.jp/) enrichment analyses were performed by Phyper based on Hypergeometric test. The dataset used for GO and KEGG analyses were all the differentially expressed Genes‌. Q value < 0.05 was considered statistically significant. Visualization was achieved by using the pheatmap (version1.0.12). RT-qPCR analysis Total RNA was extracted by TRI-Reagent (T-9424, Sigma, St. Louis, MO, USA) according to manufacturer’s instructions. RT-qPCR was performed with QuantiNova SYBR Green PCR kit (Qiagen GmbH, Hilden, German) as we described (Zhu et al. 2020): 2 min at 95 ℃ for denaturation, followed by 40 cycles with segments of 95 C for 5 s and 55 ℃ for 30 s. The Ct values were normalized against the house keeping gene GAPDH and analyzed by the 2−ΔΔCt method. The results were expressed as fold-change relative to the respective control. The primers were shown in Supplementary materials 1. Western blotting analysis Western blotting analysis was conducted as described (Zhou et al. 2010). The antibodies were shown in Supplementary materials 2. GAPDH was used as endogenous control. The protein levels were expressed as the relative band densities quantified by ImageJ software (NIH, Bethesda, MD, USA). Immunofluorescent staining Six µm thick of sections of liver tissues were used for immunofluorescent staining as we described (Zhou et al. 2010). Briefly, the paraformaldehyde-fixed liver sections underwent antigen retrieval and were blocked for incubation with the respective primary antibody (α-SMA, collagen Type Iα1 (Col1α1), Flag, PTBP1, or desmin) and the DyLight 594- or DyLight 488-conjugated secondary antibody. The nuclei were counterstained with Hoechst 33,342 (Sigma, St. Louis, MO, USA). The antibodies were listed in the Supplementary materials 3. The images were captured by the fluorescent microscope (Olympus, Japan) at 200-fold magnification. The immunofluorescent staining was quantified in five randomly chosen fields in the left lobe of each mouse liver by using ImageJ software. The HSCs in human livers were counted in five randomly fields in each sample at 200-fold magnification. The antibodies were shown in Supplementary materials 3. Sirius red staining and H&E staining Sirius red and H&E stainings were conducted by using the paraformaldehyde-fixed liver sections as we described (Xu et al. 2023). Briefly, for Sirius red staining, six µm thick of liver sections were incubated with picric acid-Sirius red (AMRESCO, Solon, USA) and then underwent dehydration and clearance. Hematoxylin–Eosin Staining Kit (E607318, Sangon Biotech Co, Ltd, Shanghai, China) was used for H&E staining. Briefly, after stained with Hematoxylin Staining Solution, the liver sections were differentiated with hydrochloric acid–ethanol and counterstained in Eosin Staining Solution, followed by dehydration and clearance. The images were captured by light microscope (Olympus, Japan) at 200-fold magnification. All the staining was quantified in five randomly chosen fields in the left lobe of each mouse liver by using ImageJ software and the results expressed as fold changes. Assays of liver hydroxyproline Liver hydroxyproline levels were assayed by the Hydroxyproline Assay Kit (MAK008, Sigma, St. Louis, USA) according to the manufacturer´s instructions as we described (Xu et al. 2023). Briefly, after hydrolyzed in hydrochloric acid and dried, the liver samples were mixed with the chloramine T/oxidation buffer mixture and incubated for 5 min, followed by incubation with DMAB reagent. Absorbance was read at a wavelength of 560 nm. The results were expressed as μg/g of liver. Srebp1c mRNA stability assay After infected with 50 × multiplicity of infection (MOI) of Ad.mPTBP1 (adenovirus encoding mouse PTBP1, Hanbio Technology Co. Ltd, Shanghai, China) or the Ad.Control for 48 h (Zhu et al. 2020), HSCs in 6-well plates were treated with Actinomycin D (Act.D, AA007, Genview, Beijing, China) at 5 μg/ml or DMSO. Total RNA was extracted from the cells at different time points by TRI-Reagent (T3934, Sigma, St. Louis, USA). The Srebp1c mRNA was analyzed by RT-qPCR analysis. RBP immunoprecipitation (RIP) assay HSCs were infected with 50 MOI of Ad.mPTBP1 for 48 h (Zhu et al. 2020) and then harvested. RIP assay was conducted by a RIP kit (Bes5101, Bersin Biotech Inc., Guangzhou, China) according to the manufacturer’s instructions. Briefly, HSCs were lysed with the RIP lysis buffer and treated with DNase. 10% of the cell lysates were used as input material. The others were incubated with 2 μg of anti-PTBP1 antibody (57,246, Cell Signaling Technology, Inc., Danvers, MA, USA) or rabbit IgG (2729, Cell Signaling Technology) overnight at 4 ºC, followed by incubation with protein A/G magnetic beads for 1 h at 4 °C for co-immunoprecipitation. After proteinase K digestion, the co-immunoprecipitated RNAs were extracted and the enrichment of Srebp1c mRNA was verified by RT-PCR and consequent 2% agarose gel electrophoresis. The PCR primers were listed in Supplementary materials 1. RNA pull-down assay For further confirming the interaction of PTBP1 and SREBP1c mRNA, RNA pull-down assay was conducted. Biotin-labeled RNA probes were synthesized by the company (Guangzhou Geneseed Biotech. Co., Ltd, Guangzhou, China) and the sequence of RNA probe was same as the published sequence which was shown to be bound by PTBP1 in hepatocytes (Wu et al. 2024). The control sequence was the antisense sequence. RNA Pull-down assay was performed by using PureBinding RNA–Protein pull-down Kit (P0201, Guangzhou Geneseed Biotech. Co., Ltd, Guangzhou, China) according to the manufacturer's instructions. Briefly, the cultured HSCs were collected and underwent lyses and centrifugation. A portion of the supernatant was used as input and the other was used for incubated with the Biotin-labeled RNA probes or the Biotin-labeled control probes, followed by incubation with streptavidin magnetic beads. The RNA–protein complexes were eluted from the magnetic beads for Western blotting analyses of PTBP1. Statistical analysis All the results were expressed as mean ± standard deviation (S.D.) from at least 3 biological replicates. Statistical analysis was done using Prism (version 8, GraphPad Software, San Diego, CA, USA). The comparisons were made using unpaired two-tailed t-tests. P values less than 0.05 were considered statistically significant. Results Ptbp1 silencing leads to the increases in the pro-fibrotic gene expressions and the decreases in the anti-fibrotic gene expressions in the activated HSCs in vitro For examining the effect of PTBP1 on pro- and anti-fibrotic gene expressions in culture-activated HSCs, RNA sequencing was performed by using mouse activated HSCs received mouse siPTBP1(m) or the siControl. Heatmap analyses suggested that at least 57 pro-fibrotic gene expressions were increased (Fig. 1a) and 8 anti-fibrotic gene expressions were reduced (Fig. 1b) by Ptbp1 silencing as compared with the respective control. Of note, among them included the most potent fibrogenic factors TGFβ and PDGF (Kisseleva and Brenner 2021; Dewidar et al. 2019) and their receptors, signaling transducer Smad3, the important ECM Col1α1 and Col3α1 (Delgado et al. 2021) (Fig. 1a), the key transcriptional regulation factor Srebp1in inhibition of HSC activation (Trivedi et al. 2021) and the pro-apoptotic genes Bax and Caspase7 (Kim et al. 2012; Yu et al. 2010) (Fig. 1b). GO enrichment analyses of the all annotated different expression genes suggested that PTBP1 affected mRNA metabolism, ECM organization, cell proliferation and apoptosis, liver regeneration, lipid metabolic process, wound healing (Fig. 1c). KEGG enrichment analyses of the all annotated different expression genes indicated that PTBP1 impacted multiple signaling pathways such as TGFβ, Wnt, MAPK, PI3K/Akt, and AMPK (Fig. 1d). These pathways were closely associated with induction or inhibition of HSC activation and liver fibrosis (Zhu et al. 2020; Lee and Friedman 2011; Biernacka et al. 2011; Arteaga et al. 2016; Marrone et al. 2018; Silva et al. 2009). The same samples as in Fig. 1a were used for confirming the expressions of the important pro- and anti-fibrotic genes shown in heatmap by RT-qPCR analyses and the results revealed that Ptbp1 silencing increased the expression of at least 9 pro-fibrosis genes including Tgfβ2, Pdgfc, Tgfβ receptor1 (Tgfβr1), Pdgf receptor-β (Pdgfrβ), Pdgf receptor-α (Pdgfrα), Smad3, Col1α1, Col3α1, tissue inhibitor of metalloproteinase2 (Timp2) (Fig. 1e), whereas Ptbp1 silencing led to the reductions in the expression of at least 3 anti-fibrosis genes including Srebp1c, Bax, and Caspase7 (Fig. 1e). We also examined all the genes mentioned above in LX-2 received human siPTBP1 or siControl by RT-qPCR analyses and the data demonstrated the same results as shown in mouse HSCs except that no significant change in Timp2 expression was observed following Ptbp1 silencing (Fig. 1f). siRNA knockdown efficiency was shown by RT-qPCR (Fig. 1e, f) and Western blotting analyses (Fig. 1g).Fig. 1Ptbp1 silencing in the activated HSCs up-regualtes pro-fibrotic gene expression and down-regulates anti-fibrotic gene expression in vitro. a,b Heatmap of hierarchical clustering of 65 significantly differentially expressed mRNAs between two groups of the cultured mouse HSCs received siPTBP1(m) or siControl. Out of the 65 genes, 57 pro-fibrotic gene expressions were increased (a, red color) and 8 anti-fibrotic gene expressions were reduced (b, blue color) by Ptbp1 silencing as compared to the respective control received siControl. c,d GO and KEGG enrichment analyses of the all annotated different expression genes between two groups of HSCs as described in a,b. Q value < 0.05. e,f RT-qPCR analyses of the mRNA levels of the important pro-fibrotic or anti-fibrotic genes shown in Heatmap a,b in the culture-activated mouse HSCs (e) and LX-2 (f) received siPTBP1(m) or siPTBP1 (h) or siControl, respectively. n.s. = not significantly. *P < 0.05. g Western blotting analyses of PTBP1 in two groups of the cultured mouse HSCs received siPTBP1(m) or siControl and in two groups of the cultured LX-2 received siPTBP1(h) or siControl Ptbp1 silencing in the activated HSCs up-regualtes pro-fibrotic gene expression and down-regulates anti-fibrotic gene expression in vitro. a,b Heatmap of hierarchical clustering of 65 significantly differentially expressed mRNAs between two groups of the cultured mouse HSCs received siPTBP1(m) or siControl. Out of the 65 genes, 57 pro-fibrotic gene expressions were increased (a, red color) and 8 anti-fibrotic gene expressions were reduced (b, blue color) by Ptbp1 silencing as compared to the respective control received siControl. c,d GO and KEGG enrichment analyses of the all annotated different expression genes between two groups of HSCs as described in a,b. Q value < 0.05. e,f RT-qPCR analyses of the mRNA levels of the important pro-fibrotic or anti-fibrotic genes shown in Heatmap a,b in the culture-activated mouse HSCs (e) and LX-2 (f) received siPTBP1(m) or siPTBP1 (h) or siControl, respectively. n.s. = not significantly. *P < 0.05. g Western blotting analyses of PTBP1 in two groups of the cultured mouse HSCs received siPTBP1(m) or siControl and in two groups of the cultured LX-2 received siPTBP1(h) or siControl Ptbp1+/− mice exhibit higher levels of pro-fibrotic gene expressions in livers and enhance liver fibrosis as compared with the respective control of Ptbp1+/+ mice in mouse model of TAA-induced liver fibrosis For examining the effect of Ptbp1 knockdown on liver fibrosis in vivo, Ptbp1+/− mice and Ptbp1+/+ mice were received TAA as shown in the up panel of Fig. 2a and the two groups of liver samples were used for RNA sequencing and RT-qPCR. RNA sequencing revealed that at least 47 pro-fibrosis gene expressions in Ptbp1+/− mice were increased as compared with the control of Ptbp1+/+ mice, which included the important pro-fibrosis gene: Tgfβ2, Pdgfα, Pdgfd, Tgfβr2, Pdgfrα, Pdgfrβ, Timp1, and α-SMA (the marker for HSC activation), Col1α1, and Col3α1 (Fig. 2a). These results were confirmed by RT-qPCR analyses of the same liver samples (Fig. 2d). GO enrichment analyses of the all annotated different expression genes indicated that PTBP1 affected mRNA metabolism, ECM organization, cell proliferation and apoptosis, inflammatory response, lipid metabolic process, and wound healing (Fig. 2b). KEGG enrichment analyses of the all annotated different expression genes suggested that PTBP1 influenced at least the following signaling pathways: TGFβ, Hedgehog, MAPK, PI3K/Akt, and AMPK (Fig. 2c), which were closely related to induction or inhibition of HSC activation and liver fibrosis (Zhu et al. 2020; Lee and Friedman 2011; Biernacka et al. 2011; Arteaga et al. 2016; Marrone et al. 2018; Silva et al. 2009; Choi et al. 2010). The inhibitory effects of PTBP1 on HSC activation and liver fibrosis were also demonstrated by hydroxyproline levels (Fig. 2e), α-SMA expression (the staining of α-SMA), Col level (the staining of Col1α1 and Sirius red staining) and ‌the structural alterations (H&E staining) of the liver (Fig. 2f) in Ptbp1+/+ mice livers as compared with the respective control of Ptbp1+/− mice livers. Western blotting analyses (Fig. 2g) further confirmed the inhibitory effects of PTBP1 on Col1α1 and Col3α1 expression (the most important ECM for liver fibrosis) and on α-SMA level (the marker for HSC activation) by using the same liver samples. We also examined HSC activation, Col1α1, liver fibrosis, and liver structure in livers from Ptbp1+/− mice and Ptbp1+/+ mice (without TAA treatment) and no difference was observed between the two groups (shown in Supplementary materials 4).Fig. 2Ptbp1+/− mice exhibit higher levels of pro-fibrotic gene expressions and intensify liver fibrosis as compared with the respective control of Ptbp1+/+ mice. a Heatmap of hierarchical clustering of 47 significantly differentially expressed mRNAs between livers from Ptbp1+/− mice and Ptbp1+/+ mice. Both groups of mice were received TAA (shown in the up panel) and 47 pro-fibrotic genes were shown to be up-regulated (red color) in Ptbp1+/− mice when compared to the respective control of Ptbp1.+/+ mice. b,c GO and KEGG enrichment analyses of all the annotated different expression genes between two groups of livers from the mice as described in a. Q value < 0.05. d RT-qPCR analyses of the mRNA levels of the important pro-fibrotic genes shown in the Heatmap by using the same liver samples as described in a. *P < 0.05. e Assays of liver hydroxyproline level in the two groups of mice as described in a. *P < 0.05. f Immunofluorescent staining of α-SMA as well as Col1α1, and Sirius staining and H&E stainings of livers from the two groups of mice as described in a. The right histogram demonstrated the relative area of the respective staining. Scale bar = 50 μm. *P < 0.05. g Western blotting analyses of Col1α1, Col3α1 and α-SMA levels in livers from two groups of mice as described in a. The lower histogram showed the relative densities of the bands. *P < 0.05 Ptbp1+/− mice exhibit higher levels of pro-fibrotic gene expressions and intensify liver fibrosis as compared with the respective control of Ptbp1+/+ mice. a Heatmap of hierarchical clustering of 47 significantly differentially expressed mRNAs between livers from Ptbp1+/− mice and Ptbp1+/+ mice. Both groups of mice were received TAA (shown in the up panel) and 47 pro-fibrotic genes were shown to be up-regulated (red color) in Ptbp1+/− mice when compared to the respective control of Ptbp1.+/+ mice. b,c GO and KEGG enrichment analyses of all the annotated different expression genes between two groups of livers from the mice as described in a. Q value < 0.05. d RT-qPCR analyses of the mRNA levels of the important pro-fibrotic genes shown in the Heatmap by using the same liver samples as described in a. *P < 0.05. e Assays of liver hydroxyproline level in the two groups of mice as described in a. *P < 0.05. f Immunofluorescent staining of α-SMA as well as Col1α1, and Sirius staining and H&E stainings of livers from the two groups of mice as described in a. The right histogram demonstrated the relative area of the respective staining. Scale bar = 50 μm. *P < 0.05. g Western blotting analyses of Col1α1, Col3α1 and α-SMA levels in livers from two groups of mice as described in a. The lower histogram showed the relative densities of the bands. *P < 0.05 Targeted over-expression of Ptbp1 in HSCs in mice affects pro-fibrotic and anti-fibrotic gene expressions and attenuates TAA- or BDL-induced liver fibrosis For further testing the effects of PTBP1 on the pro- and anti-fibrotic gene expressions in HSCs shown in vitro, targeted over-expression of Ptbp1 in HSCs in mice was employed. Two groups of mice received AAV6-Flag-mPTBP1 or AAV6-Control during TAA treatment as shown in the up panel of Fig. 3a and HSCs were isolated the livers for RT-qPCR. Figure 3a revealed that, compared with the control, the targeted over-expression of Ptbp1 in HSCs in vivo led to the decreases in the pro-fibrotic gene expressions (Tgfβ2, Pdgfc, Tgfβr1, Pdgfrβ, Pdgfrα, Smad3, Col1α1, Col3α1, and α-SMA) and the increases in the anti-fibrotic gene expressions (Srebp1c, Bax, and Caspase7) in HSCs. Based on the results, another two groups of mice treated as in Fig. 3a were used for examining the effects of the targeted Ptbp1 over-expression in HSCs in vivo on HSC activation and liver fibrosis. The results indicated that Ptbp1 over-expression in HSCs in vivo reduced the levels of liver hydroxyproline (Fig. 3b), α-SMA, Col1α1, liver fibrosis, and the change of liver structure (Fig. 3c) as compared with the respective control. Double immunofluorescent staining of flag indicated the effective targeted over-expression of Ptbp1 in HSCs in mouse livers (Fig. 3d).Fig. 3Targeted expression of Ptbp1 in HSCs in mice affects pro-fibrotic and anti-fibrotic gene expressions and reduces TAA- or BDL-induced mouse liver fibrosis. a RT-qPCR analyses of the mRNA levels of the pro-fibrotic and anti-fibrotic genes (shown in Fig. 1e, f) in HSCs isolated from mouse livers received AAV6-Flag-mPTBP1 or AAV6-Control during TAA treatment (shown in the up panel). n.s. = not significantly. *P < 0.05. b,f Assays of liver hydroxyproline level in mice received AAV6-Flag-mPTBP1 or AAV6-Control during treatment with TAA as described in a (b) or BDL (f). BDL treatment was shown in the up panel of e. *P < 0.05. c,e Immunofluorescent staining of α-SMA as well as Col1α1, and Sirius staining and H&E staining of livers from mice received AAV6-Flag-mPTBP1 or AAV6-Control during treatment with TAA as described in a (c) or BDL (e). The right histogram demonstrated the relative area of the respective staining. Scale bar = 50 μm. *P < 0.05. d Double immunofluorescent staining of flag (green color) in HSCs (red color, shown by desmin) in livers from mice received TAA and AAV6-Flag-mPTBP1 as described in a. The targeted expression of PTBP1 in HSCs in mouse livers was indicated by white arrows. Scale bar = 50 μm. g Western blotting analyses of Col1α1, Col3α1 and α-SMA levels in livers from two groups of mice treated as described in a and e. The lower histogram showed the relative densities of the bands. *P < 0.05. h RT-qPCR analyses of inflammation factors in livers from two groups of mice treated as described in a and e. *P < 0.05. i RIP assay showing the binding of PTBP1 to Srebp1c mRNA in the cultured HSCs infected with Ad.mPTBP1. Srebp1c mRNA levels were examined by RT-PCR and the products were underwent 2% agarose gel electrophoresis. j RNA pull-down assay. The cultured LX-2 were collected for RNA pull down assay. The RNA–protein complexes were eluted from the magnetic beads for Western blotting analyses of PTBP1. k Srebp1c mRNA stability assay showing the inhibitory effect of PTBP1 on Srebp1c mRNA degradation in the culture-activated mouse HSCs infected with Ad.mPTBP1 or Ad.Control. RT-qPCR analysis was performed for detecting Srebp1c mRNA levels. *P < 0.05 Targeted expression of Ptbp1 in HSCs in mice affects pro-fibrotic and anti-fibrotic gene expressions and reduces TAA- or BDL-induced mouse liver fibrosis. a RT-qPCR analyses of the mRNA levels of the pro-fibrotic and anti-fibrotic genes (shown in Fig. 1e, f) in HSCs isolated from mouse livers received AAV6-Flag-mPTBP1 or AAV6-Control during TAA treatment (shown in the up panel). n.s. = not significantly. *P < 0.05. b,f Assays of liver hydroxyproline level in mice received AAV6-Flag-mPTBP1 or AAV6-Control during treatment with TAA as described in a (b) or BDL (f). BDL treatment was shown in the up panel of e. *P < 0.05. c,e Immunofluorescent staining of α-SMA as well as Col1α1, and Sirius staining and H&E staining of livers from mice received AAV6-Flag-mPTBP1 or AAV6-Control during treatment with TAA as described in a (c) or BDL (e). The right histogram demonstrated the relative area of the respective staining. Scale bar = 50 μm. *P < 0.05. d Double immunofluorescent staining of flag (green color) in HSCs (red color, shown by desmin) in livers from mice received TAA and AAV6-Flag-mPTBP1 as described in a. The targeted expression of PTBP1 in HSCs in mouse livers was indicated by white arrows. Scale bar = 50 μm. g Western blotting analyses of Col1α1, Col3α1 and α-SMA levels in livers from two groups of mice treated as described in a and e. The lower histogram showed the relative densities of the bands. *P < 0.05. h RT-qPCR analyses of inflammation factors in livers from two groups of mice treated as described in a and e. *P < 0.05. i RIP assay showing the binding of PTBP1 to Srebp1c mRNA in the cultured HSCs infected with Ad.mPTBP1. Srebp1c mRNA levels were examined by RT-PCR and the products were underwent 2% agarose gel electrophoresis. j RNA pull-down assay. The cultured LX-2 were collected for RNA pull down assay. The RNA–protein complexes were eluted from the magnetic beads for Western blotting analyses of PTBP1. k Srebp1c mRNA stability assay showing the inhibitory effect of PTBP1 on Srebp1c mRNA degradation in the culture-activated mouse HSCs infected with Ad.mPTBP1 or Ad.Control. RT-qPCR analysis was performed for detecting Srebp1c mRNA levels. *P < 0.05 Two groups of mice received AAV6-Flag-mPTBP1 or AAV6-Control during BDL treatment were also used for examining the effect of targeted over-expression of Ptbp1 in HSCs in vivo on liver fibrosis as shown in the up panel of Fig. 3e. Immunofluorescent staining of α-SMA and Col1α1 in the livers (Fig. 3e), Sirius and H&E staining of the livers (Fig. 3e), and liver hydroxyproline assay (Fig. 3f) demonstrated the same results shown in Fig. 3c and b. Western blotting analyses of the livers from the two mouse models of liver fibrosis confirmed that Ptbp1 over-expression in HSCs in vivo reduced the levels of Col1α1, Col3α1, and α-SMA (Fig. 3g). Several of inflammation factors in the livers from the two mouse models of liver fibrosis were also detected and the results indicated that the levels of at least IL-1β, IL-6, and TNFα declined in Ptbp1 over-expression in HSCs in vivo as compared with the respective control received AAV6-Control (Fig. 3h). Among PTBP1-regulated anti-fibrotic genes, Srebp1c plays a critical role in maintaining HSCs in the quiescent state (Trivedi et al. 2021). In hepatocytes, PTBP1 binds to Srebp1c mRNA, thus increasing Srebp1c mRNA stability (Wu et al. 2024). Thereby, we tested whether PTBP1 bound to Srebp1c mRNA in HSCs and affected Srebp1 mRNA stability by infecting HSCs with Ad.mPTBP1 or Ad.Control. RIP assay (Fig. 3i) showed the binding of PTBP1 to Srebp1 mRNA in HSCs which was confirmed by RNA pull-down assay (Fig. 3j). RT-PCR revealed an evident positive effect of PTBP1 on Srebp1c mRNA stability in HSCs (Fig. 3k). Ptbp1expression is reduced in the activated HSCs in vitro and in vivo Since targeted over-expression of Ptbp1 in HSCs inhibited HSC activation in vivo (shown in Fig. 3), ‌Ptbp1 expression levels might be changed during the process of HSC activation. Therefore, HSCs isolated from mouse livers were cultured for different time periods and Ptbp1 expressions at both protein and mRNA levels were showed to decline with the prolonged culture time (Fig. 4a, b), which were accompanied with the increases in the levels of Col1α1, and α-SMA. We also detected the effects of Ptbp1 over-expression on the levels of Col1α1, Col3α1, and α-SMA by infecting culture-activated HSCs with Ad.mPTBP1 or Ad.Control. The results revealed the inhibitory effects of PTBP1 over-expression on the expressions of Col1α1, Col3α1, and α-SMA (Fig. 4c) in HSCs in vitro, which were in line with the results shown in vivo.Fig. 4Ptbp1expression declines in the activated HSCs in vitro and in vivo. a,b Western blotting analysis or RT-qPCR analysis of the expression of Ptbp1, α-SMA, or Col1α1 in HSCs in vitro. HSCs from mice livers were cultured for 1, 3, 7, or 14 days and the levels of Ptbp1, α-SMA, or Col1α1 at different time points were examined by Western blotting analysis (a) and RT-qPCR analysis (b), respectively. In a, the right histogram showed the relative densities of the bands. *P < 0.05. c Western blotting analysis of PTBP1, COL1α1, COL3α1, and α-SMA levels in the activated HSCs received Ad.mPTBP1 or Ad.Control in vitro. The mouse activated HSCs were infected with 50 MOI of Ad.mPTBP1 or Ad.Control for 48 h, followed by Western blotting analysis. The lower histogram showed the relative densities of the bands. *P < 0.05. d,e Western blotting analysis (d) and RT-qPCR analysis (e) of Ptbp1 expression in HSCs in livers from 4 groups mice received TAA, vehicle, BDL, or sham operation, respectively. The right histogram in d showed the relative densities of the bands. *P < 0.05. f Double immunofluorescent staining of PTBP1 (green color) in HSCs (red color, shown by desmin) in livers from 5 patients of liver fibrosis. Ptbp1 expression in HSCs was indicated by white arrows. The lower histogram showed the relative number of total HSCs and PTBP1-positive HSCs. Scale bar = 50 μm. *P < 0.05 Ptbp1expression declines in the activated HSCs in vitro and in vivo. a,b Western blotting analysis or RT-qPCR analysis of the expression of Ptbp1, α-SMA, or Col1α1 in HSCs in vitro. HSCs from mice livers were cultured for 1, 3, 7, or 14 days and the levels of Ptbp1, α-SMA, or Col1α1 at different time points were examined by Western blotting analysis (a) and RT-qPCR analysis (b), respectively. In a, the right histogram showed the relative densities of the bands. *P < 0.05. c Western blotting analysis of PTBP1, COL1α1, COL3α1, and α-SMA levels in the activated HSCs received Ad.mPTBP1 or Ad.Control in vitro. The mouse activated HSCs were infected with 50 MOI of Ad.mPTBP1 or Ad.Control for 48 h, followed by Western blotting analysis. The lower histogram showed the relative densities of the bands. *P < 0.05. d,e Western blotting analysis (d) and RT-qPCR analysis (e) of Ptbp1 expression in HSCs in livers from 4 groups mice received TAA, vehicle, BDL, or sham operation, respectively. The right histogram in d showed the relative densities of the bands. *P < 0.05. f Double immunofluorescent staining of PTBP1 (green color) in HSCs (red color, shown by desmin) in livers from 5 patients of liver fibrosis. Ptbp1 expression in HSCs was indicated by white arrows. The lower histogram showed the relative number of total HSCs and PTBP1-positive HSCs. Scale bar = 50 μm. *P < 0.05 For detecting Ptbp1 expression during the process of HSC activation in vivo, 4 groups of mice were respectively received TAA, vehicle, BDL, or sham operation as shown in the up panel of Fig. 4d. HSCs were isolated from the livers for Western blotting and RT-qPCR analyses and the results demonstrated the declines in PTBP1 protein and mRNA levels in HSCs from TAA- or BDL-treated mice as compared with the respective control (Fig. 4d, e). We also examined Ptbp1 levels in HSCs in fibrotic livers from patients by double immunofluorescent staining and the results indicated that the number of PTBP1-positive HSCs in fibrotic area was decreased as compared with the control in the adjacent normal area (Fig. 4f), suggesting the reduction in PTBP1 expression in human HSCs of the fibrotic livers. PTBP1 inhibits PI3K/Akt signaling pathway in HSCs in vitro and in vivo Given that PI3K/Akt signaling pathway was markedly enriched in KEGG analyses (Figs. 1d, 2c), PTBP1might significantly influence PI3K/Akt signaling pathway in HSCs. We detected the levels of phosphorylation of Akt1(p-Akt1) in cultured HSCs with enforced expression of Ptbp1 or in TAA-induced liver fibrosis of Ptbp1+/+ mice and Ptbp1+/− mice. The results showed that PTBP1 reduced p-Akt1level in HSCs in vitro and in vivo (Fig. 5), which indicated that PTBP1 inhibited PI3K/Akt signaling pathway in HSCs.Fig. 5Ptbp1inhbits PI3k/Akt signaling pathway in HSCs in vitro and in vivo. a Western blotting analysis of p-Akt1 level in HSCs. Mouse HSCs in 6-well plastic plate were transfected with pcDNA3.1-PTBP1(encoding mouse PTBP1) or pcDNA3.1. HSCs were harvested for Western blotting analyses 48 h after transfection. The right histogram showed the relative densities of the bands. *P < 0.05. b Double immunofluorescent staining of p-Akt1 (red color) in HSCs (green color, shown by desmin) in livers. The same liver samples as in Fig. 2a (Ptbp1+/− mice and Ptbp1.+/+ mice were treated with TAA for 6 weeks) were used for double immunofluorescent staining. The right histogram showed the relative number of total HSCs and p-Akt1-positive HSCs. Scale bar = 50 μm. *P < 0.05 Ptbp1inhbits PI3k/Akt signaling pathway in HSCs in vitro and in vivo. a Western blotting analysis of p-Akt1 level in HSCs. Mouse HSCs in 6-well plastic plate were transfected with pcDNA3.1-PTBP1(encoding mouse PTBP1) or pcDNA3.1. HSCs were harvested for Western blotting analyses 48 h after transfection. The right histogram showed the relative densities of the bands. *P < 0.05. b Double immunofluorescent staining of p-Akt1 (red color) in HSCs (green color, shown by desmin) in livers. The same liver samples as in Fig. 2a (Ptbp1+/− mice and Ptbp1.+/+ mice were treated with TAA for 6 weeks) were used for double immunofluorescent staining. The right histogram showed the relative number of total HSCs and p-Akt1-positive HSCs. Scale bar = 50 μm. *P < 0.05 Discussion HSC activation is based on the changes of gene expression in HSCs. RBPs are a class of proteins that exert the crucial role in the post-transcriptional regulation by controlling mRNA fate (Gerstberger et al. 2014; Cook et al. 2011; Garcia-Maurino et al. 2017), which are essentially involved in the process of HSC activation and thus significantly affect liver fibrogenesis. Some of the RBPs were demonstrated to promote liver fibrosis. This research indicated that the multifunctional PTBP1, a key RBP in inhibiting neuron differentiation, exerted an inhibitory effect on HSC activation and liver fibrogenesis, which functioned through regulating a lot of important pro- or anti-fibrotic gene expression. PTBP1-downregulated pro-fibrotic genes included at least the most potent fibrogenic factors, the receptors, signal transducer, and the important ECM, whereas PTBP1-upregulated the anti-fibrotic genes included at least the key transcriptional factor Srebp1c and two pro-apoptotic genes. Ptbp1 bound to Srebp1c mRNA and inhibited its degradation. Moreover, PTBP1 inhibited PI3K/Akt pathway in HSCs. PTBP1 level declined not only in the activated mouse HSCs but also in HSCs of human fibrotic liver samples. These results all evidently pointed to a previously unrecognized negative effect of PTBP1 on HSC activation and liver fibrogenesis. RBPs regulate every event in a RNA molecule lifetime, thus they are closely involved in the processes of the physiology and pathology of human body (Gebauer et al. 2021; Fang et al. 2024). PTBP1 played a key role in inhibition of neuron differentiation (Yeom et al. 2018; Liang et al. 2024) and the activated HSC possesses the evident characteristics of nerve cells (Li et al. 2022; Cassiman et al. 2001). These data were in line with the effect of PTBP1 on HSC activation shown in the present researches and the multifunctional PTBP1might also play an important role in inhibition of HSC activation. It is interesting that PTBP1 induce lipogenesis in hepatocytes by stabilizing Srebp1c mRNA, thus exacerbating the development of fatty liver (Liu et al. 2018) and we showed that PTBP1 bound to and stabilized Srebp1c mRNA, thus increasing Srebp1c expression in HSCs. SREBP1c and peroxisome proliferator-activated receptor γ (PPARγ) are the crucial transcriptional factors in promoting adipocyte differentiation (Tsukamoto et al. 2008) and it is noteworthy that quiescent HSCs were once called “fat-storing cells” (Ito and Nemoto 1952) and similar to adipocytes (She et al. 2005; Tsukamoto 2005). Upon activation, quiescent HSCs lose lipid and become myofibroblastic with induced expression of type I collagen and type III collagen and the activated HSCs are similar to preadipocytes (She et al. 2005; Tsukamoto 2005). Therefore, ectopic expression of Srebp1c or Pparγ in HSCs caused morphologic and biochemical reversal of activated HSC to quiescent cells, which exerted the pivotal roles in inhibiting HSC activation (She et al. 2005; Tsukamoto 2005; Hazra et al. 2004). Based on the role of SREBP1c in inhibiting HSC activation, the positive effect of PTBP1 on Srebp1c expression in HSCs should significantly contribute to its inhibition of HSC activation and liver fibrosis. Besides PTBP1 regulation of Srebp1c in HSCs, PTBP1 was required for the increased expression of the short cytoplasmic form of CEACAM1 (CEACAM1-S) in hepatocytes (Dery et al. 2023) whereas CEACAM1-S limited hepatocyte injury and improved liver function in mouse models of acute liver injury (Dery et al. 2023). Moreover, CEACAM1-S was positively correlated with the better human liver transplant outcomes including reduced TIMP1 and proinflammatory cytokines (Dery et al. 2023). These results suggested that PTBP1 protected liver from the acute injury. Also, it should be noted that PTBP1 is involved in reducing reactive oxygen species (Yu et al. 2023), the potent inducers of liver fibrosis (Cichoz-Lach 2014), and associated with cell apoptosis (Zhang et al. 2009). PTBP1 promotes pro-apoptotic gene expression and modulates the susceptibility to caspase activation in differentiating rat cardiomyocytes (Zhang et al. 2009). The study indicated that Ptbp1 knockdown in Rat-1 fibroblasts induced a reduction of pro-apoptotic gene expression, including Caspase9, Bax, and Bid (Zhang et al. 2009). Our research demonstrated the promotional effects of PTBP1 on the expression of Bax and Caspase7 in activated HSCs. Considering that the apoptosis of the activated HSCs is an important mechanism for reversing liver fibrosis (Delgado et al. 2021), the positive effects of PTBP1 on the expression of pro-apoptotic genes in activated HSCs coincided with its inhibition of liver fibrosis. HSC activation is based on the fibrogenic factor-induced changes of the expression of a large number of genes. Our results revealed the negative effect of PTBP1 on the expression of TGFβ and PDGF, the most potent fibrogenic factors (Kisseleva and Brenner 2021; Dewidar et al. 2019), in HSCs and livers. The promotional effect of PTBP1 on TGFβ mRNA degradation in the neural cell line PC12 cell (Liu et al. 2024) was in agreement with our result. PI3K/Akt signaling pathway is a important pathway for HSC activation and liver fibrogenesis (Zhu et al. 2020; Shavva et al. 2026; Lopez-Sanchez et al. 2014). The inhibition of PI3K/Akt pathway in HSCs by PTBP1 might be associated with the influences of PTBP1 on the roles of TGFβ or PDGF in HSCs, since both TGFβ and PDGF are the upstream signals of PI3K/Akt pathway. We noticed the contradictory findings regarding the role of PTBP1 in liver fibrosis. Propofol was shown to improved ischemia reperfusion-induced liver fibrosis by reducing the interaction among HOXA11-AS, PTBP1, and HDAC4 in HSCs (Luo et al. 2023). The inclusion of the research was that Propofol improved liver fibrosis by reducing the interaction among HOXA11-AS, PTBP1, and HDAC4 in HSCs (Luo et al. 2023), but no results indicated the effects of Propofol on the interaction among HOXA11-AS, PTBP1, and HDAC4 in HSCs. The effects of propofol on PTBP1 in HSCs in vitro and in vivo were also lacking and thus the role of PTBP1 in propofol inhibition of liver fibrosis was elusive. We provided the in vivo data by targeted over-expression of Ptbp1 in HSCs in vivo, confirming the effects of PTBP1 on the pro- and anti-fibrotic gene expressions, HSC activation, and liver fibrosis. Another research suggested the involvement of PTBP1 in the promotional effect of lncRNA Helf on liver fibrosis (Han et al. 2023). The authors indicated that lnc-Helf interacted with PTBP1 to promote its interaction with PIK3R5 mRNA in HSCs, resulting in HSC activation and liver fibrosis. But no data indicated the interaction between PTBP1 and PIK3R5 mRNA in HSCs in the research and there were not the data from PTBP1 gain-of-function or loss-of-function experiments in HSCs in vivo, which were the key results. Zhang provided a result: Long non-coding RNA H19 inhibited let-7 miRNAs bioavailability and thus exacerbated BDL-induced hepatic inflammatory response (Zhang et al. 2019), which was in concordance with the finding that H19-BDL livers developed more severe fibrosis than H19 Null-BDL livers (Song et al. 2017), whereas H19 decreased Ptbp1 expression in livers and PTBP1 facilitated the bioavailability of let-7 miRNAs (Zhang et al. 2019). These results from Zhang seemed to suggest another mechanism underlying the inhibitory effect of PTBP1 on liver fibrosis. Although the results showed the reduction in PTBP1 levels in HSCs in human fibrotic livers, we could not confirm the correlation between the degree of liver fibrosis and the level of PTBP1 in HSCs in patients, since these patients have hepatic tumors. Conclusions Our researches demonstrated that the multifunctional PTBP1 functioned as an inhibitor in HSC activation and liver fibrogenesis. This research offered new insights into the roles of PTBP1, a key RBP in inhibiting neuron differentiation, in liver fibrosis. Given that PTBP1 targeted lots of important pro- and anti-fibrotic genes, RBP PTBP1 may serve as a potential therapeutic strategy for treatment of liver fibrosis. Supplementary Information Supplementary Material 1. Supplementary Material 1.